Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 31;17(1):139.
doi: 10.3390/nu17010139.

Associations Between Hemoglobin and Serum Iron Levels and the Risk of Mortality Among Patients with Coronary Artery Disease

Affiliations

Associations Between Hemoglobin and Serum Iron Levels and the Risk of Mortality Among Patients with Coronary Artery Disease

Qing Li et al. Nutrients. .

Abstract

Background: This study aimed to investigate the relationship between hemoglobin and serum iron levels and mortality risk in patients with coronary artery disease (CAD).

Methods: We analyzed data from 3224 patients with CAD using Cox proportional hazards regression models to assess the association of hemoglobin and serum iron levels with cardiovascular and all-cause mortality from the Guangdong coronary artery disease cohort.

Results: Over a median follow-up period of 8.9 years, 636 patients died, including 403 from cardiovascular causes. Higher hemoglobin and serum iron levels were linked to a reduced risk of cardiovascular and all-cause mortality. Patients in the highest quartiles of hemoglobin and serum iron levels had multivariable-adjusted hazard ratios (HRs) of 0.62 (95% CI, 0.46-0.85) and 0.51 (95% CI, 0.37-0.69) for cardiovascular mortality and 0.64 (95% CI, 0.50-0.83) and 0.67 (95% CI, 0.53-0.85) for all-cause mortality, compared with those in the lowest quartile. A one-standard-deviation increase in hemoglobin and serum iron levels corresponded to a 19% and 24% reduction in cardiovascular mortality risk and a 19% reduction in all-cause mortality risk for both factors. Restricted cubic spline analysis revealed L-shaped and U-shaped associations between hemoglobin and serum iron levels and cardiovascular and all-cause mortality, respectively.

Conclusions: Hemoglobin and serum iron levels were significantly associated with lower risks of cardiovascular and all-cause mortality in patients with CAD. Further research is needed to evaluate the effects of iron supplementation in these patients.

Keywords: coronary artery disease; hemoglobin; iron; mortality; prospective cohort study.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Restricted cubic splines in Cox models of hemoglobin levels with cardiovascular (A) and all-cause (B) mortality risk. Adjustments were made for age; sex; alcohol drinking status; smoking status; body mass index; systolic blood pressure; diastolic blood pressure; fasting plasma glucose; non-high-density lipoprotein cholesterol; triglycerides; duration of coronary artery disease; estimated glomerular filtration rate; type of coronary artery disease (acute and chronic); C-reactive protein; the use of anti-diabetic, anti-platelet, cholesterol-lowering, and anti-hypertensive drugs; and serum iron levels. The middle solid line represents the hazard ratio, while the upper and lower dashed lines indicate the 95% confidence interval.
Figure 2
Figure 2
Restricted cubic splines in Cox models of serum iron levels with cardiovascular (A) and all-cause (B) mortality risk. Adjustments were made for age; sex; alcohol drinking status; smoking status; body mass index; systolic blood pressure; diastolic blood pressure; fasting plasma glucose; non-high-density lipoprotein cholesterol; triglycerides; duration of coronary artery disease; estimated glomerular filtration rate; type of coronary artery disease (acute and chronic); C-reactive protein; the use of anti-diabetic, anti-platelet, cholesterol-lowering, and anti-hypertensive drugs; and hemoglobin levels. The middle solid line represents the hazard ratio, while the upper and lower dashed lines indicate the 95% confidence interval.

Similar articles

References

    1. Kobayashi M., Suhara T., Baba Y., Kawasaki N.K., Higa J.K., Matsui T. Pathological Roles of Iron in Cardiovascular Disease. Curr. Drug Targets. 2018;19:1068–1076. doi: 10.2174/1389450119666180605112235. - DOI - PMC - PubMed
    1. Bi Y., Ajoolabady A., Demillard L.J., Yu W., Hilaire M.L., Zhang Y., Ren J. Dysregulation of iron metabolism in cardiovascular diseases: From iron deficiency to iron overload. Biochem. Pharmacol. 2021;190:114661. doi: 10.1016/j.bcp.2021.114661. - DOI - PubMed
    1. Xu J., Jia Z., Knutson M.D., Leeuwenburgh C. Impaired iron status in aging research. Int. J. Mol. Sci. 2012;13:2368–2386. doi: 10.3390/ijms13022368. - DOI - PMC - PubMed
    1. Dhingra R., Vasan R.S. Age as a risk factor. Med. Clin. N. Am. 2012;96:87–91. doi: 10.1016/j.mcna.2011.11.003. - DOI - PMC - PubMed
    1. Stauder R., Thein S.L. Anemia in the elderly: Clinical implications and new therapeutic concepts. Haematologica. 2014;99:1127–1130. doi: 10.3324/haematol.2014.109967. - DOI - PMC - PubMed

LinkOut - more resources